ProQR (PRQR) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ProQR Therapeutics N.V. has entered into an underwriting agreement to sell 18 million ordinary shares with the option for underwriters to purchase an additional 2.7 million shares. This public offering is facilitated by representatives from Evercore Group L.L.C. and Cantor Fitzgerald & Co., signaling a significant move in the market for investors interested in the biotech sector.
For further insights into PRQR stock, check out TipRanks’ Stock Analysis page.